POAI (Predictive Oncology) Total Current Assets : $4.57 Mil (As of Sep. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Predictive Oncology Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Predictive Oncology's total current assets for the quarter that ended in Sep. 2024 was $4.57 Mil.

Predictive Oncology Total Current Assets Historical Data

The historical data trend for Predictive Oncology's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Predictive Oncology Total Current Assets Chart

Predictive Oncology Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

0.80

1.51

29.46

23.36

10.08

Predictive Oncology Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Current Assets	Get a 7-Day Free Trial															13.52	10.08	6.56	6.89	4.57

Predictive Oncology Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Predictive Oncology's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	8.729	+	0.334	+	0.494	+	0.521
	=	10.08

Predictive Oncology's Total Current Assets for the quarter that ended in Sep. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	3.079	+	0.464	+	0.504	+	0.52
	=	4.57

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Predictive Oncology (NAS:POAI) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Predictive Oncology's Liquidation Value for the quarter that ended in Sep. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	3.079	-	5.531	+	0.75 * 0.464	+	0.5 * 0.504
=	-1.85

Predictive Oncology Total Current Assets Related Terms

Thank you for viewing the detailed overview of Predictive Oncology's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Predictive Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Predictive Oncology Inc (NAS:POAI) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.91 43rd Street, Suite 110, Pittsburgh, PA, USA, 55121

Website

https://www.predictive-oncology.com

Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.

Executives

Robert L Myers	officer: CHIEF FINANCIAL OFFICER	4765 BEACON HILL ROAD, EAGAN MN 55122
Nuzum Charles Lee Sr	director	633 1ST STREET WEST, SONOMA CA 95476
Veena Rao	director	2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
Matthew Hawryluk	director	C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
St. Clair Gregory Sr	director	1645 WHITLEY DRIVE, HARRISBURG PA 17111
Nancy Chung-welch	director	P O BOX 1572, PEPPERELL MA 01463
Pamela Bush	officer: Chief Business Officer	2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
Daniel E Handley	director	1142 S. DIAMOND BAR BLVD. #464, DIAMOND BAR CA 91765
Raymond F Vennare	director	2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
David Stewart Smith	director	151 WASHINGTON STREET, PITTSBURGH PA 15218
J Melville Engle	director	1 REMINGTON COURT, NAPA CA 94558
Jenkins Christina Lee Md	director	2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
Carl I. Schwartz	10 percent owner	20155 N.E. 38TH COURT, UNIT 3104, AVENTURA FL 33180
Richard L Gabriel	director	900 COCOANUT AVENUE, SARASOTA FL 34236
Pamela S Prior	director	2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121